Are hematopoietic colony-stimulating factors useful in association with chemotherapy in the treatment of HIV-related non-Hodgkin's lymphomas?

Annals of Oncology

Volumn 7, Issue 3, 1996, Pages 233-237

  Errante, D ^a   Vaccher, E ^a   Tirelli, U ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Colony stimulating factors; HIV; Non Hodgkin's lymphoma; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; BLEOMYCIN; COLONY STIMULATING FACTOR; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LOMUSTINE; METHOTREXATE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; TENIPOSIDE; VINCRISTINE; VINDESINE;

BONE MARROW SUPPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA; LEUKOPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0029914428     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010565     Document Type: Short Survey

References (24)

1. Folks TM, Kessler SW, Orestein JM et al. Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow. Science 1988; 242: 919-22.
2. Zon LJ, Arkim C, Groopman JE. Hematologic manifestations of the human immunodeficiency virus (HIV). Br J Haematol 1987; 66: 251-6.
3. Scadden DT, Zon LJ, Groopman JE. Pathophysiology and management of HIV-associated hematologic disorders. Blood 1989; 74: 1455-63.
4. Neidhart JA. Hematopoietic cytokines. Current use in cancer therapy. Cancer 1993; 72: 3381-6.
5. Bronchud M. Can hematopoietic growth factors be used to improve the success of cytotoxic chemotherapy? Anti-cancer drugs 1993; 4: 127-39.
6. Vose JM, Armitage JO. Clinical applications of hematopoietic growth factors. J Clin Oncol 1995; 4: 1023-35.
7. Miles SA. The use of hematopoietic growth factors in HIV infection and AIDS-related malignancies. Cancer Invest 1991; 9: 229-38.
8. Mitsuyasu RT. Use of recombinant interferons and hematopoietic growth factors in patients infected with human immunodeficiency virus. Rev Infect Dis 1991; 13: 979-84.
9. American Society of Clinical Oncology recommendation for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 1994; 12: 2471-508.
10. Boogaerts M, Cavalli F, Cortés-Funes H et al. Granulocyte growth factors: Achieving a consensus. Ann Oncol 1995; 6: 237-44.
11. Gill PS, Levine AM, Krailo M et al. AIDS-related malignant lymphoma: Results of prospective treatment trials. J Clin Oncol 1987; 5: 1322-8.
12. Bermudez MA, Grant KM, Rodvien R et al. Non-Hodgkin's lymphoma in a population with or at risk for acquired immunodeficiency syndrome: Indications for intensive chemotherapy. Am J Med 1989; 86: 71-6.
13. Sawka CA, Shepherd FA, Brandwein J et al. Treatment of AIDS-related non-Hodgkin's lymphoma with a twelve-week chemotherapy program. Leuk Lymph 1992; 8: 213-20.
14. Gisselbrecht C, Oksenhendler E, Tirelli U et al. Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy. Am J Med 1993; 95: 188-96.
15. Remick SC, McSharry JJ, Wolf BC et al. Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1691-702.
16. Taillan B, Garnier G, Ferrari E et al. MACOB-B chemotherapy for the treatment of high-grade lymphomas in patients with HIV-1 infection. Acta Haematol 1993; 89: 10-2.
17. Sparano JA, Wiernik PH, Strack M et al. Infusional cyclophosphamide, doxorubicin and etoposide in HIV-related non-Hodgkin's lymphoma: A follow-up report of a highly active regimen. Leuk Lymph 1994; 14: 263-71.
18. Tirelli U, Errante D, Oksenhendler E et al. Prospective study with combined low-dose chemotherapy and zidovudine in 37 patients with poor-prognosis AIDS-related non-Hodgkin's lymphoma. Ann Oncol 1992; 3: 843-7.
19. Levine AM, Wernz JC, Kaplan L et al. Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. JAMA 1991; 266: 84-8.
20. Kaplan LD, Khan JO, Crowe S et al. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: Results of a randomized trial. J Clin Oncol 1991; 9: 929-40.
21. Walsh C, Wernz JC, Levine A et al. Phase I trial of m-BACOD and granulocyte macrophage colony stimulating factor in HIV-associated non-Hodgkin's lymphoma. JAIDS 1993; 6: 265-71.
22. Tirelli U, Sorio R, Monfardini S et al. Recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with AIDS-related tumors and chemotherapy-induced bone-marrow suppression. J AIDS 1990; 11: 1115 (Letter).
23. Tirelli U, Vaccher E. Economic and clinical evaluation of therapy of HIV-related non-Hodgkin's lymphoma with chemotherapy and granulocyte colony-stimulating factor (G-CSF). Eur J Cancer 1994; 30A(10): 1589-90 (Letter).
24. Lyman GH, Lyman CG, Sanderson RA et al. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 1993; 85: 1935-36.